Introduction
============

Noonan syndrome (NS) is an autosomal dominant disorder, mainly characterized by proportionate short stature, facial and muscoloskeletal dysmorphisms and congenital heart defects (most commonly pulmonary valve stenosis and hypertrophic cardiomiopathy) with an incidence rate between 1:1,000 and 1:2,500 live births ([@b1-or-30-02-0553]). Further findings may include cryptorchidism, bleeding diathesis, lymphatic dysplasia and mild to moderate developmental delay/intellectual disability (DD/ID). A myeloproliferative disorder (NS/MPD) can occasionally be diagnosed in infants with NS. The clinical course of NS/MPD is usually benign with spontaneous remission. However, various cases with an aggressive course resembling juvenile myelomonocytic leukemia (JMML) have been described ([@b2-or-30-02-0553]--[@b6-or-30-02-0553]). JMML is a rare clonal myelodysplastic-myeloproliferative disorder typical of infancy and early childhood, characterized by spontaneous *in vitro* proliferation of bone marrow and peripheral blood hematopoietic progenitors in the absence of exogenous growth factors, due to selective hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) ([@b7-or-30-02-0553]). Hepatosplenomegaly, lymphoadenopathy, anemia, thrombocytopenia, and fever, variably associated with symptoms of non-hematopoietic organ infiltration, are common clinical findings in JMML. The fulfillment of the following laboratory criteria is required for JMML diagnosis: an absolute monocyte count \>1,000/μl, \<20% bone marrow blasts and the absence of t (9;22) or BCR/ABL rearrangement. Apart from such mandatory criteria, JMML patients may present with a high white blood cell count (\>10,000/μl), immature myeloid precursors on a peripheral smear and increased fetal hemoglobin (HbF) for age. Monosomy 7 is quite frequently noted ([@b8-or-30-02-0553]).

Both NS and JMML are characterized by hyperactivation of the RAS/MAPK signaling pathway. In NS, germline missense mutations in genes such as PTPN11, KRAS, SOS1, RAF1, BRAF, SHOC2, NRAS and CBL ([@b9-or-30-02-0553]--[@b19-or-30-02-0553]) have been documented. In JMML, mutually exclusive somatic mutations of PTPN11, KRAS, NRAS and NF1 genes can be found in \~75% of cases. NS is associated with germline PTPN11 mutations in \~50% of the patients, while somatic PTPN11 mutations are found in 35% of children with JMML. This gene encodes for the ubiquitously expressed non-receptor protein tyrosine phosphatase (PTP) SHP-2, which is implicated in a variety of intracellular signaling cascades mediated by growth factors, cytokines, hormones and cell adhesion molecules ([@b20-or-30-02-0553],[@b21-or-30-02-0553]). SHP-2 is also involved in several developmental processes, in particular semi-lunar valvulogenesis ([@b22-or-30-02-0553]) and hematopoietic cell differentiation ([@b23-or-30-02-0553],[@b24-or-30-02-0553]). PTPN11 mutations favor either the basal activity or the response to inducing events of the catalytically active conformation of SHP-2, resulting in gain of function ([@b11-or-30-02-0553]). The PTPN11 mutational spectrum has been shown to be different in JMML, NS/MPD and NS without any hematological abnormalities ([@b5-or-30-02-0553]).

We previously demonstrated that flow cytometric evaluation of the absolute count of peripheral blood (PB) CD34^+^ cells and the apoptotic rate is a simple and repeatable technique, useful for early detection of clonal evolution in acquired aplastic anemia. In children with *de novo* or secondary refractory anemia with blast excess (RAEB) we observed a typical pattern of a high PB CD34^+^ count associated with a low apoptotic rate, sometimes evident months before the appearance of the complete clinical image ([@b25-or-30-02-0553]).

In the present study, we performed a functional evaluation of the circulating hematopoietic progenitors in a series of NS patients. Clonogenic tests in the absence or in the presence of increasing concentrations of GM-CSF and three-color flow cytometric analysis for CD45, CD34, and Annexin V were performed using the PB of 27 patients with NS and 5 patients with JMML. The different functional patterns were compared to identify a possible NS subgroup worthy of stringent hematological follow-up for an increased risk of MPD development.

Materials and methods
=====================

Patients
--------

Included in the present study were 27 patients admitted to Department of Pediatrics with a clinical diagnosis of NS (independently of their mutational status and the presence of hematological anomalies). Three patients had a myeloproliferative disorder (NS/MPD), with monocytosis, atypical monocytoid cells, myelodysplastic features and granulocyte precursors in PB, thrombocytopenia and hepato-splenomegaly ([@b2-or-30-02-0553]--[@b6-or-30-02-0553]). Five patients with a diagnosis of JMML, fulfilling the EWOG-MDS criteria ([@b8-or-30-02-0553]) were also studied. PB samples were collected in EDTA at diagnosis. Further blood samples were collected and analyzed in NS patients when hematological anomalies (e.g. anemia, thrombocytopenia, leukocytosis, splenomegaly, lymphadenopathy) and/or alterations of the functional pattern of circulating hematopoietic progenitors were observed. NS/MPD and JMML patients were evaluated at various stages during follow-up and treatment. Ethics committee approval and informed consent of the parents of the patients were obtained.

Genomic mutational analysis
---------------------------

Genomic DNA was isolated from 200 μl of PB by the QIAamp DNA Blood Mini kit (Qiagen, Germantown, MD, USA). A molecular analysis of PTPN11, KRAS, SOS1, RAF1, BRAF, SHOC2, NRAS and CBL was performed as previously described ([@b11-or-30-02-0553]--[@b20-or-30-02-0553]).

Absolute count of CD34^+^ cells and the apoptotic index
-------------------------------------------------------

Flow cytometric analysis was performed within 2 h after venipuncture. The absolute count of CD34^+^ cells and the apoptotic rate were evaluated by a three-color fluorescence for CD45, CD34 and Annexin V as follows. A total of 5×10^5^ nucleated cells were incubated for 20 min at 4°C with anti-CD34 PE (8G12; Becton-Dickinson, San José, CA, USA) and anti-CD45 PerCP (2D1; BD Biosciences, Franklin Lakes, NJ, USA). After incubation and red cell lysis by ammonium chloride, the samples were washed in cold phosphate-buffered saline (PBS) and incubated with Annexin V-fluorescein isothiocyanate (FITC) (Apoptosis Detection kit; R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. The cells were then analyzed in a Coulter Epics XL2 (IL, Bedford, MA, USA) cytometer equipped with an argon laser. CD34^+^ cells were identified by a sequential gating strategy according to the ISHAGE protocol ([@b26-or-30-02-0553]). Absolute CD34 counts were assessed by a two-platform method with a Sysmex K4500 counter (Sysmex Corporation, Kobe, Japan). At least 100 CD34^+^ cells were evaluated in each experiment.

Cell cultures
-------------

Low-density mononuclear cells (2×10^5^) obtained from the patient PB by density centrifugation over Ficoll-Hypaque gradient were plated in multi well plates in 250 μl Iscove's modified Dulbecco's medium (IMDM) containing 30% fetal calf serum (FCS) (both from Sigma-Aldrich, St. Louis, MO, USA), 0.3% noble agar and 100 U/ml rhIL-3 and decreasing concentrations (20, 10, 5, 1, 0.1 ng/ml) of rhGM-CSF (both from Invitrogen Life Technologies, Carlsbad, CA, USA). After 14 days, single aggregates of \>40 cells were scored as CFU-GMs. GM-CFU assay was also performed without GM-CSF stimulation. GM-CFU assay in the same culture conditions was also performed in 21 pediatric controls (median age, 9.0; range, 1--18 years).

Statistical analysis
--------------------

The patients were divided into 3 groups: NS, NS/MPD and JMML. Historical controls (n=68) from our laboratory were utilized for the absolute count of CD34^+^ in PB and the apoptotic rate ([@b25-or-30-02-0553]).

For the absolute count of CD34^+^ cells and apoptotic rate, the values for each patient were compared with the mean control value adjusted for age, as previously published ([@b25-or-30-02-0553]).

The cell culture data and the absolute count of CD34^+^ cells and the apoptotic rate results were analyzed using the non-parametric Kruskal-Wallis test. Pairwise comparisons for the disease groups were performed for each of the GM-CSF concentration utilized in the cell cultures, as well as for the 4 variables analyzed in the test (absolute CD34^+^, percentage of CD34^+^/Annexin V^+^, absolute CD34^+^ to the mean age group value ratio, percentage of CD34^+^/Annexin V^+^ to the mean age group value ratio). Fisher's exact probability test was utilized for correlations between the groups.

Results
=======

Mutational spectrum of the patients
-----------------------------------

The mutational spectrum of our series of NS, NS/MPD and JMML patients is shown in [Table I](#tI-or-30-02-0553){ref-type="table"}.

Monocyte counts
---------------

All JMML patients showed monocytosis \>1,000/μl. Ten out of the 27 NS patients showed monocytosis \>1,000/μl, which included the 3 NS/MPD patients ([Tables I](#tI-or-30-02-0553){ref-type="table"} and [II](#tII-or-30-02-0553){ref-type="table"}).

Platelet counts
---------------

All JMML patients showed thrombocytopenia as well as 1 out of the 3 NS/MPD patients. In the other NS patients, the platelet counts were in the range of normality, without a correlation with monocyte counts (R=0.016) ([Table I](#tI-or-30-02-0553){ref-type="table"}).

Absolute CD34^+^ cell count and apoptotic rate
----------------------------------------------

The PB absolute CD34^+^ cell counts and apoptotic rates in the different groups of patients are shown in [Tables I](#tI-or-30-02-0553){ref-type="table"} and [II](#tII-or-30-02-0553){ref-type="table"}. In JMML and NS/MPD patients, we observed high levels of circulating CD34^+^ cells with a low apoptotic rate. In NS patients, CD34^+^ cell counts were normal, whereas their apoptotic rate was significantly lower than that in the controls (p\<0.01). Concerning the absolute CD34^+^cell count, statistically significant differences were noted among the NS and JMML (p=0.001), NS and NS/MPD (p\<0.05), controls and JMML (p\<0.01), and controls and NS/MPD patients (p\<0.05). In contrast, no differences in the absolute CD34^+^ cell count were observed between the controls and NS or between the NS/MPD and JMML patients. Normalizing the absolute CD34^+^cell count for age (absolute CD34^+^ to mean age group value ratio), the results from the pairwise comparison did not change.

A pairwise comparison of the Annexin V^+^ percentage showed a statistically significant decrease in the apoptotic rate in each disease group when compared with the controls: NS (p\<0.01), NS/MPD (p\<0.05), JMML(p\<0.01); whereas no significant difference was observed between NS/MPD and JMML, JMML and NS, and NS/MPD and NS patients. When the percentage of Annexin V^+^ cells was normalized for age (percentage of Annexin V^+^/CD34^+^ cells to mean age group value ratio), the results for the pairwise comparison did not change.

Cell cultures
-------------

In the JMML patients, the clonogenic assays from PB showed hypersensitivity to GM-CSF and spontaneous CFU-GM growth (except in one patient previously treated with chemotherapy at another center who did not show spontaneous CFU-GM growth) ([Table I](#tI-or-30-02-0553){ref-type="table"}). In 3 out of 3 NS/MPD patients we observed hypersensitivity to GM-CSF (in patient NS/MPD3 during the follow-up) and in 2 out of 3 spontaneous CFU-GM growth was noted. In 2 NS patients (NS13 and NS19) we observed hypersensitivity to GM-CSF, and no spontaneous CFU-GM growth. One NS patient (NS11) showed hypersensitivity to GM-CSF and spontaneous CFU-GM growth. This patient had a favorable clinical outcome, and the clonogenic assays performed 6 months later showed normal results.

We observed a significant difference in the distribution and in the median values of CFU-GM among the 3 groups (JMML, NS, NS/MPD) ([Table II](#tII-or-30-02-0553){ref-type="table"}). [Table III](#tIII-or-30-02-0553){ref-type="table"} (pairwise comparisons of GM-CSF-stimulated clonogenic assays) showed that at different GM-CSF concentrations, JMML patients were significantly more responsive to GM-CSF than both the controls and NS patients. Concerning unstimulated cultures, a significant growth advantage was observed also in NS/MPD when compared with the controls and NS patients ([Table III](#tIII-or-30-02-0553){ref-type="table"}). Specifically, clonogenic assays without GM-CSF were able to distinguish between NS and NS/MPD patients. Fisher's exact probability test showed a significant correlation between the groups in the unstimulated colony growth tests (0% in controls, 4.2% in NS, 80% in JMML, 66.7% in NS/MPD, p\<0.001).

Follow-up of NS and NS/MPD patients
-----------------------------------

Six NS patients showed isolated monocytosis \>1,000/μl, 2 NS patients showed isolated hyper-responses to GM-CSF, 5 NS patients showed an isolated increase in circulating CD34^+^ cells. In all of these patients a 12-month follow-up showed no alterations in clinical findings. Patients NS11 and NS/MPD1 showed monocytosis \>1,000/μl, a hyper-response to GM-CSF, CFU-GM growth without GM-CSF stimulation, high circulating CD34^+^ counts with a low apoptotic rate. In these 2 NS patients a clinical and laboratory follow-up was performed. Patient NS11 carrying the Glu76Asp PTPN11 mutation, was phenotypically characterized by polyhydramnios in the prenatal history, typical facial dysmorphisms, pulmonic stenosis, bilateral cryptorchidism and normal neuropsychomotor development. His clinical follow-up in the following months was normal, and a laboratory hematologic evaluation performed 12 months later showed normal response to GM-CSF, no spontaneous colony growth and normal CD34^+^ cell and monocyte counts.

Patient NS/MPD1 was first evaluated at the age of 2 months while she was in the cardiac surgery unit due to obstructive hypertrophic cardiomyopathy. A clinical diagnosis of NS was confirmed by the molecular analysis of the PTPN11 gene, that revealed the Phe285Ser mutation. A preliminary hematological evaluation evidenced only mild hepatomegaly and monocytosis. Clonogenic assays and flow cytometry showed hypersensitivity to GM-CSF, spontaneous CFU-GM growth, increased circulating CD34^+^ cells with a low apoptotic rate. At the age of 12 months, the patient showed splenomegaly, thrombocytopenia and monocytosis, with the presence in the peripheral blood smear of 10% of atypical monocytoid cells, moderate myelodysplastic features and granulocyte precursors. Bone marrow aspirate showed mild myelodysplasia and the presence of 15% of atypical monocytoid elements. A polymerase chain reaction (PCR) for bcr/abl rearrangement was negative. The HUMARA assay performed on peripheral blood populations was normal, excluding a frank JMML evolution and suggesting a polyclonal myeloproliferative disorder, described in NS ([@b2-or-30-02-0553]). Hence, a diagnosis of NS/MPD was made. Thrombocytopenia and splenomegaly persisted over the following months, and the clinical course worsened, with a progressive development of lymphatic dysplasia with thoracic duct ectasia, progressive severe respiratory insufficiency, pleural effusion and exitus at the age of 20 months for acute cardiopulmonary failure.

Patients NS/MPD2 and NS/MPD3 were diagnosed in the first month of life presenting a myeloproliferative disorder. [Table IV](#tIV-or-30-02-0553){ref-type="table"} shows the clinical and laboratory follow-up of the NS/MPD patients, and [Fig. 1](#f1-or-30-02-0553){ref-type="fig"} shows a detailed follow-up of patient NS/MPD1.

Discussion
==========

Genetic diseases associated with a high tumor risk are models for the study of carcinogenesis. A close correlation is often observed between such genetic conditions and specific acquired neoplastic diseases. NS and JMML were shown to be strictly correlated to each other. Indeed, the same signal transduction pathway (RAS/MAPK) is hyperactivated both in NS and in JMML, with an involvement of the same genes. Moreover, NS patients presented an increased risk of developing JMML or, more frequently, a transient myeloproliferative disorder associated with Noonan syndrome (NS/MPD).

Strictly correlated to the hyperactivation of the RAS/MAPK pathway is the hypersensitivity to GM-CSF observed in JMML ([@b7-or-30-02-0553]).

In the present study, we conducted a molecular study of a cohort of NS and JMML patients with a functional evaluation of their circulating hematopoietic progenitors, and correlated the results with the clinical-hematological course. In particular, our aim was to evaluate the circulating CD34^+^ cell count and apoptotic rate and to relate such findings with *in vitro* colony growth (in the absence and with increasing concentrations of GM-CSF), hematological features and the clinical history of each patient. The analyses were performed on PB, even though the biological variability of hematopoietic progenitor counts and clonogenic assays in PB is higher than in bone marrow. A bone marrow aspirate would have been unethical in NS patients without any sign of a hematological disease.

Even though a constitutional GM-CSF hypersensitivity has been suggested in NS ([@b6-or-30-02-0553],[@b27-or-30-02-0553]), we observed hypersensitivity to GM-CSF in only 6 of the 27 NS patients. One of them developed a myeloproliferative disorder 12 months later (NS/MPD1) and 2 patients (NS/MPD2 and NS/MPD3) had a transient myeloproliferative syndrome at the time of the study. In patient NS/MPD3, a hyper-response to GM-CSF was observed during the follow-up, but not at diagnosis. The other 3 NS patients with GM-CSF hypersensitivity had normal hematological profiles. These data suggest that the response to GM-CSF is variable in NS patients.

PTPN11 mutations in JMML affect amino acids differently from those involved in NS ([@b5-or-30-02-0553],[@b28-or-30-02-0553],[@b29-or-30-02-0553]). Somatic JMML-associated mutations are predicted to result in a stronger SHP-2 gain of function than germ-line mutations described in NS, and the leukemic transformation in NS seems related to cooperating molecular lesions ([@b5-or-30-02-0553]). In our NS series, one patient (NS5) carried the Gly503Glu PTPN11 mutation, also described in JMML. Interestingly, this patient showed a normal hematological profile without hypersensitivity to GM-CSF, but his mother, who presented with a short stature and typical facial appearance, as revealed by anamnestic data and family photographs, died due to non-Hodgkin lymphoma.

In a previous study, we observed in normal subjects a progressive decrease in circulating CD34^+^ cells and a progressive increase in their apoptotic rate from the first months of life to adult age ([@b25-or-30-02-0553]). An increase in circulating CD34^+^ cells has been described in myelofibrosis with myeloid metaplasia in adults ([@b30-or-30-02-0553]) and in RAEB in adults ([@b31-or-30-02-0553]) and in children, associated with a low apoptotic rate ([@b25-or-30-02-0553]). Here, we observed a similar behavior in the JMML and in the NS/MPD patients. PB CD34^+^ cell counts in the majority of our NS patients were normal, but the apoptotic CD34^+^ cell rate was significantly lower than that in the controls, as in JMML and NS/MPD. Previous studies have pointed to an increased proliferative activity of hematopoietic progenitors in NS. Our results allow us to identify NS as a disease with a lower-than-normal apoptotic activity of circulating hematopoietic progenitors. This increase in the survival of hematopoietic progenitors appears to be a hallmark of NS patients.

Two out of 3 NS/MPD patients shared the same functional pattern of JMML, characterized by high circulating CD34^+^ cell counts with a very low apoptotic rate, hypersensitivity to GM-CSF and spontaneous CFU-GM growth.

The present data represent the complex hematopoietic functional profile of a series of NS patients and suggest that the evaluation of the absolute CD34^+^ count and the apoptotic rate as well as CFU-GM assay performed on PB could be a non-invasive and repeatable method that can facilitate the identification of NS patients with a higher risk of myeloproliferative evolution for whom an intensified hematological follow-up program is justified.
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![Detailed functional follow-up of patient NS/MPD1. (A) Peripheral blood absolute CD34^+^ cell counts (CD34/μl) and apoptotic rate (% Annexin V^+^) and absolute monocyte counts (monocytes/μl) are shown. (B) Numbers of peripheral blood CFU-GMs cultured with decreasing concentrations of GM-CSF or without GM-CSF stimulation (unstimulated) are shown.](OR-30-02-0553-g00){#f1-or-30-02-0553}

###### 

Mutational spectrum, WBC, PLT and monocyte counts, CD34^+^ absolute count and apoptotic rate, CFU-GM from peripheral blood in a series of NS, NS/MPD and JMML patients.

  Patient   Mutated gene   Mutation    Hypersensitivity to GM-CSF   Unstimulated colony growth   Annexin V^+^/CD34^+^ (%)   CD34 (/μl)   WBC (10^3^/μl)   Monocytes (10^3^/μl)   PLT (10^3^/μl)           
  --------- -------------- ----------- ---------------------------- ---------------------------- -------------------------- ------------ ---------------- ---------------------- ---------------- ------- -----
  NS1       PTPN11         Gln79Arg    No                           No                           8.5                        L            3.6              N                      11.9             0.740   284
  NS2       PTPN11         Asn58His    No                           No                           26.1                       H            7                N                      11.6             0.400   262
  NS3       PTPN11         Tyr63Cys    No                           No                           16.1                       N            2.5              L                      8.3              0.300   428
  NS4       PTPN11         Gly503Arg   No                           No                           2.56                       L            3.42             L                      17.1             1.720   331
  NS5       PTPN11         Gly503Glu   No                           No                           7.6                        L            3.6              N                      7.3              0.900   249
  NS6       PTPN11         Asn308Ser   No                           No                           12                         L            6.2              H                      10.3             0.690   297
  NS7       PTPN11         Leu261His   No                           No                           10                         L            2.9              N                      5.8              0.470   416
  NS8       PTPN11         Leu261His   No                           No                           0                          L            4.8              N                      12.0             0.770   376
  NS9       PTPN11         Leu261His   No                           No                           10                         L            17.52            H                      7.3              0.600   277
  NS10      PTPN11         Phe285Ile   No                           No                           7.9                        L            3.8              N                      7.7              0.410   218
  NS11      PTPN11         Glu76Asp    Yes                          Yes                          1.0                        L            12               H                      12.0             1.140   300
  NS12      PTPN11         Glu139Asp   No                           No                           17.8                       L            2.2              L                      7.3              0.510   198
  NS13      PTPN11         Asp61Asn    Yes                          No                           4.1                        L            13.8             H                      15.3             0.840   212
  NS14      SOS            Ile252Thr   No                           No                           27.7                       H            2.6              L                      6.4              0.450   259
  NS15      SOS            Thr266Lys   No                           No                           8.8                        L            16.2             H                      12.5             0.620   291
  NS16      SOS            Arg552Gly   No                           No                           18.2                       L            1.3              L                      4.3              0.340   259
  NS17      SOS            Glu433Lys   No                           No                           0                          L            7.75             N                      15.5             1.420   422
  NS18      RAF1           Ser257Leu   No                           No                           8                          L            2.5              L                      6.4              0.540   253
  NS19      SOS            Met269Thr   Yes                          No                           4.4                        L            5.2              N                      8.7              1.100   182
  NS20      n.d.           n.d.        No                           No                           11.2                       N            4.5              L                      12.2             1.110   184
  NS21      KRAS           Gln22Arg    No                           No                           15.7                       L            5.6              N                      9.44             0.630   551
  NS22      BRAF           Leu597Val   No                           No                           0.09                       L            7.1              H                      7.9              1.600   397
  NS23      RAF1           Pro261Ser   No                           No                           25                         H            5                N                      12.6             1.450   384
  NS24      SHOC2          Ser2Gly     No                           No                           6.8                        L            8.5              N                      17.0             0.700   482
  NS/MPD1   PTPN11         Phe285Ser   Yes                          Yes                          2.4                        L            58.0             H                      14.5             2.500   399
  NS/MPD2   PTPN11         Asp61Asn    Yes                          Yes                          0.2                        L            1,374            H                      43.5             5.520   54
  NS/MPD3   PTPN11         Asp61Asn    Yes                          No                           1.6                        L            205.7            H                      20.2             2.550   167
  JMML1     n.d.           n.d.        Yes                          Yes                          2.1                        L            193.6            H                      9.3              1.900   55
  JMML2     PTPN11         Glu76Gly    Yes                          Yes                          12.1                       N            44               H                      8.8              1.380   31
  JMML3     PTPN11         Gly503Val   Yes                          No                           7.2                        L            49.6             H                      3.1              1.070   45
  JMML4     NF1            n.d.        Yes                          Yes                          0.4                        L            109.8            H                      11.2             1.430   15
  JMML5     n.m.           n.d.        Yes                          Yes                          0.4                        L            232              H                      36.2             7.610   71

NS, Noonan syndrome patients (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution (n=3); JMML, juvenile myelomonocytic leukemia patients (n=5). For '% AnnexinV^+^/CD34^+^' and 'CD34^+^/μl' categories: 'L' (low), indicated samples in which the values of Annexin V expression on CD34^+^ cells or the CD34^+^ absolute count were lower than the average −2 SD, compared to the reference values for the same age groups (reviewed in ref. [@b25-or-30-02-0553]); 'N' (normal) indicated samples in which the value was included in the average values ± 1 SD; 'H' (high) indicated samples in which the value was higher than the average +2 SD. Patient NS/MPD3 developed GM-CSF hypersensitivity during follow-up ([Table IV](#tIV-or-30-02-0553){ref-type="table"}). WBC, white blood count; PLT, platelets. n.d., not determined; n.m., no mutation.

###### 

Circulating monocytes, peripheral blood CD34^+^ cells, their apoptotic rate and CFU-GMs in a series of NS, NS/MPD and JMML patients.

  Clinical parameters        Controls           NS                 NS/MPD                 JMML
  -------------------------- ------------------ ------------------ ---------------------- ----------------------
  Monocytes (/μl)            600 (200--900)     695 (300--1,720)   2,550 (2,500--5,520)   1,600 (1,070--7,600)
  CD34^+^ (/μl)              5.2 (1.8--23.1)    4.9 (1.3--17.5)    205.7 (58--1,374)      109.8 (44--232)
  Annexin V^+^/CD34^+^ (%)   17.6 (2.8--49.6)   8.6 (0.0--27.7)    1.4 (0.2--2.4)         2.1 (0.4--12.1)
  GM-CSF (20 ng/ml)          9 (0--26)          4 (0--34)          36 (0--84)             46 (18--258)
  GM-CSF (10 ng/ml)          5 (0--18)          2 (0--30)          38 (0--76)             40 (10--244)
  GM-CSF (5 ng/ml)           3 (0--18)          1 (0--24)          38 (0--50)             42 (6--262)
  GM-CSF (1 ng/ml)           1 (0--16)          1 (0--23)          34 (0--62)             32 (6--264)
  GM-CSF (0.1 ng/ml)         0 (0--14)          0 (0--8)           26 (0--36)             30 (2--240)
  Unstimulated               0 (0--0)           0 (0--4)           4 (0--32)              18 (0--84)

NS, Noonan syndrome patients (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution (n=3); JMML, myelomonocytic leukemia patients (n=5). CFU-GMs from 2×10^5^ circulating mononuclear cells were cultured in the presence of decreasing GM-CSF concentrations and without GM-CSF (unstimulated). Data are provided as mean value (range).

###### 

Pairwise comparisons of the GM-CSF-stimulated clonogenic assay in the disease groups.

  Pair              GM-CSF (20 ng/ml)   GM-CSF (10 ng/ml0   GM-CSF (5 ng/ml)   GM-CSF (1 ng/ml)   GM-CSF (0.1 ng/ml)   Unstimulated
  ----------------- ------------------- ------------------- ------------------ ------------------ -------------------- --------------
  Controls-NS       0.248               1.000               1.000              1.000              1.000                1.000
  Controls-NS/MPD   1.000               1.000               1.000              1.000              0.460                **0.010**
  Controls-JMML     0.079               **0.038**           **0.022**          **0.010**          **0.007**            **0.000**
  NS-JMML           **0.001**           **0.002**           **0.004**          **0.004**          **0.003**            **0.000**
  NS-NS/MPD         0.671               0.808               0.903              0.786              0.674                **0.016**
  NS/MPD-JMML       1.000               1.000               1.000              1.000              1.000                1.000

NS, Noonan syndrome patients, (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution, (n=3); JMML, myelomonocytic leukemia patients, (n=5). Bold print indicates statistically significant p-values (p\<0.05; Kruskal-Wallis test). CFU-GM from circulating mononuclear cells cultured in the presence of decreasing GM-CSF concentrations or without GM-CSF (unstimulated).

###### 

Functional follow-up of 3 NS/MPD patients with myeloproliferative evolution.

                                                            NS/MPD1    NS/MPD2   NS/MPD3                     
  --------------------------------------------------------- ---------- --------- --------- ------- --------- --------
  Age at T~0~                                               2 months             10 days           1 month   
  WBC (/μl)                                                 14,500     8,200     43,500    8,480   20,200    16,000
  Monocytes (/μl)                                           2,500      1,400     5,520     620     2,550     1,280
  CD34^+^ (/μl)                                             58         150       1,374     13      205       45
  Annexin V^+^ (%)                                          2.4        7.5       0.2       0.8     1.6       3.0
  Hyper-response to GM-CSF                                  +++        ++        +++       No      No        +++
  Spontaneous CFU growth                                    ++         ++        \+        No      No        No
  Circulating dysplastic monocytes with myeloid dysplasia   No         +++       ++        No      \+        No
  Hepatosplenomegaly                                        No         ++        No        No      ++        No
  Thrombocytopenia                                          No         +++       ++        No      No        No

NS/MPD, Noonan syndrome patients with myeloproliferative evolution. T~0~, first observation; T~1~, observation at 12 months.
